In contrast, in solid-tumor settings, including human epidermal growth factor receptor 2 (HER2)-positive BC and triple-negative breast cancer, PROTAC translation is more frequently constrained by an "exposure-selectivity-therapeutic window" trade-off driven by physicochemical liabilities, insufficient tumor penetration, and broad target expression. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.